Wedbush Lifts Earnings Estimates for Revolution Medicines

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Wedbush raised their Q1 2025 earnings per share estimates for Revolution Medicines in a research note issued on Wednesday, February 26th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($0.89) for the quarter, up from their prior estimate of ($0.90). Wedbush has a "Outperform" rating and a $67.00 price target on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines' Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.73) EPS, FY2026 earnings at ($3.96) EPS, FY2027 earnings at ($3.72) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at $2.90 EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11).

Several other equities analysts also recently issued reports on the company. Stifel Nicolaus reduced their price objective on Revolution Medicines from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Thursday. UBS Group upped their target price on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright upped their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday. JPMorgan Chase & Co. upped their target price on Revolution Medicines from $63.00 to $71.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC cut their target price on Revolution Medicines from $60.00 to $59.00 and set a "buy" rating for the company in a research report on Thursday. Twelve analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $66.31.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded down $2.40 during midday trading on Monday, hitting $38.34. 1,576,369 shares of the company's stock were exchanged, compared to its average volume of 1,333,457. The stock's 50 day moving average price is $42.15 and its 200-day moving average price is $46.22. The firm has a market cap of $6.45 billion, a P/E ratio of -10.68 and a beta of 1.45. Revolution Medicines has a twelve month low of $29.00 and a twelve month high of $62.40.

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently bought and sold shares of the business. IFP Advisors Inc bought a new stake in Revolution Medicines in the fourth quarter worth $34,000. Quarry LP bought a new stake in Revolution Medicines in the third quarter worth $82,000. Sterling Capital Management LLC boosted its holdings in Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock worth $86,000 after purchasing an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock worth $90,000 after purchasing an additional 1,613 shares in the last quarter. Finally, Kapitalo Investimentos Ltda bought a new stake in Revolution Medicines in the fourth quarter worth $104,000. 94.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 11,714 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $531,815.60. Following the transaction, the insider now directly owns 325,056 shares of the company's stock, valued at approximately $14,757,542.40. This represents a 3.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thilo Schroeder purchased 1,304,347 shares of the company's stock in a transaction dated Thursday, December 5th. The stock was bought at an average cost of $46.00 per share, for a total transaction of $59,999,962.00. Following the completion of the purchase, the director now directly owns 2,096,612 shares of the company's stock, valued at $96,444,152. The trade was a 164.64 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 18,678 shares of company stock valued at $847,981 in the last three months. 8.00% of the stock is currently owned by company insiders.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.